<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409929</url>
  </required_header>
  <id_info>
    <org_study_id>CAEB071A2114</org_study_id>
    <nct_id>NCT00409929</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Time Lagged, Parallel Group, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AEB071 Doses Greater Than 500 mg in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of ascending single oral doses greater
      than 500 mg of AEB071 in healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ascending single oral doses of AEB071 in healthy subjects.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacokinetics of single oral doses of AEB071 at the end of study</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure inhibition of lymphocytes activation following rising oral doses of AEB071 in healthy subjects after each single dose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the pharmacokinetic/pharmacodynamic relationship of single rising oral doses of AEB071 in healthy subjects after each single dose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conduct exploratory genomic studies to identify gene expression patterns of blood cells at the end of study</measure>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEB071</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and/or female subjects from 18-55 years of age and in good health as determined
             by past medical history, physical examination, vital signs, electrocardiogram and
             laboratory tests at screening.

          -  Female subjects had to either have been surgically sterilized or be postmenopausal.

        Exclusion Criteria:

          -  Smokers

          -  Use of any prescription drug or over-the-counter medication within 2 weeks prior to
             dosing, or 2 months for inducers or inhibitors of cytochrome CYP4503A4 (paracetamol
             acceptable)

          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing

          -  A past medical history of clinically significant ECG abnormalities or a family history
             of a prolonged QT-interval syndrome

          -  History of History of fainting, hypotension when standing up, arrhythmia, acute or
             chronic bronchospastic disease

          -  History of clinically significant drug allergy; atopic allergy or a known
             hypersensitivity to any of the study drugs or drugs similar to the study drugs

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism or excretion of drugs or which may jeopardize the subject in
             case of participation in the study

          -  History of immunocompromise (including a positive HIV test result) or drug or alcohol
             abuse within the 12 months prior to dosing or evidence of such abuse or a current
             positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.

        Additional protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2006</study_first_submitted>
  <study_first_submitted_qc>December 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2006</study_first_posted>
  <last_update_submitted>October 18, 2010</last_update_submitted>
  <last_update_submitted_qc>October 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2010</last_update_posted>
  <keyword>Safety, tolerability, pharmacokinetics, pharmacodynamics, AEB071, healthy subjects, transplantation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

